Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.
D002166:Camptothecin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D003556:Cystitis / Q000139:chemically induced; D006801:Humans; D007958:Leukocyte Count; D007970:Leukopenia / Q000139:chemically induced; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced
D002166:Camptothecin